Nebenwirkungen · Uptravi
Uptravi 100 microgram film-coated tablets Uptravi 200 microgram film-coated tablets Uptravi 400 microgram film-coated tablets Uptravi 600 microgram film-coated tablets Uptravi 800 microgram film-coated tablets Uptravi 1 000 microgram film-coated tablets Uptravi 1 200 microgram film-coated tablets Uptravi 1 400 microgram film-coated tablets Uptravi 1 600 microgram film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-131266 · Präparat HOS-097037
The safety of selexipag has been evaluated in a long-term, phase 3 placebo-controlled study enrolling 1 156 adult patients with symptomatic PAH (GRIPHON study). The mean treatment duration was 76.4 weeks (median 70.7 weeks) for patients receiving selexipag versus 71.2 weeks (median 63.7 weeks) for patients on placebo. The exposure to selexipag was up to 4.2 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T09:30:00Z · SHA-256 4d844da5fca00693ca71123bccf29f73c6fef6cc58001bcf22168f0e68d3056f · Passage 334f901e6b0bf5a5a400d834a61f1d1247f2846b841339dc8542f60fda5971fe · Zeichen 319–685 im Abschnitt